Neutral impactResults
Abbott India Share Price: Is It a Good Buy After Q1 FY27 Results?
Univest 14 hrs ago·2 Sept 2026, 6:11 am
Abbott India has released its first-quarter results for FY27, showing a solid performance with steady revenue growth. The company reported a 10% increase in net sales, driven by strong demand for its nutrition and pharmaceutical products. Profit margins remained stable, reflecting efficient cost management and a focus on high-margin segments. This performance suggests the company is on a steady growth path despite broader market fluctuations.
For investors, the results indicate that Abbott India is maintaining its competitive edge in the domestic market. The consistent growth in sales and stable profitability are positive signals, especially for long-term investors. However, it is important to monitor the company's future guidance and any changes in raw material costs, which could impact margins in the coming quarters.
Excerpt from Univest
Abbott India share price around Rs 26,135. 20.3% below 52-week high of Rs 32,775. Q1 FY27 revenue Rs 1,814 crore, up 4.3% YoY. PAT Rs 429 crore, up 17.1%. PE 34x. Updated: 2 Sept 2026 • 11:41 am Abbott India's Q1 FY27 results were strong, with revenue at Rs 1,814 crore and PAT climbing 17% to Rs 429 crore. The stock…Read the original at Univest
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Abbott India (ABBOTINDIA).
- Category: Results.
Why it matters
A routine update for Abbott India. Use the price and stock snapshot to gauge how the market is responding.
